Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

Novartis’ bumper crop of new product launches in 2019 helped it post 9% sales growth in the fourth quarter, and showed that a high price hasn’t dampened take-up of new gene therapy Zolgensma.

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

Novartis already markets an IV-administered version of the gene therapy called Zolgensma.The product, which is one of the most expensive drugs in the world, is used to treat SMA in children ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

Gene-therapy Zolgensma (spinal muscular atrophy) sales of $262 million were down 6%. Promacta sales totaled $583 million, up 5% year over year. Novartis reported 2024 sales of $50.3 billion ...

Novartis' drug segment is poised for steady ... (hidradenitis suppurativa in 2023), spinal muscular atrophy drug Zolgensma (intrathecal data in 2024), and cardiovascular drug Leqvio (outcomes ...

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – onasemnogene abeparvovec (OAV101 IT) – which ...

Novartis’ efforts to strengthen its wide ... Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix, Zolgensma, Kisqali and Leqvio should fuel growth through 2030 and beyond. NVS is a Zacks Rank ...